Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

By R. Erber, A. Thurnher, Alice D. Katsen, G. Groth, H. Kerger, H. Hammes, Michael D. Menger, A. Ullrich, P. Vajkoczy. The FASEB Journal, 2004

624 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/81d5d1a24d3953cd5f693bc927a20d37f83f823c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. D. McDonald
2. N. Ferrara
3. Xiumin Wu
4. Cuiling Zhong
5. P. Wen
6. N. Vasudev
7. H. Hashizume
8. Gavin Thurston

In Molecular Biology

1. Rakesh K. Jain
2. D. McDonald
3. N. Ferrara
4. A. Armulik
5. G. Genové
6. Xiumin Wu
7. Cuiling Zhong
8. P. Baluk

In Oncology

1. D. McDonald
2. N. Vasudev
3. H. Hashizume
4. N. Ferrara
5. P. Baluk
6. A. Ostman
7. Andrew R Reynolds
8. K. Pietras

Citations in the corpus

• Hallmarks of cancer: interactions with the tumor stroma. (2010, background): “[47] R.”
• Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. (2011, background): “Double targeting of both endothelial cells and pericytes has been suggested to have better antitumoral effect than targeting of any of the cell types alone (Bergers et al., 2003; Erber et al., 2004).”
• Exciting New Advances in Neuro-Oncology (2010, background): “75 Preclinical data suggest that dual VEGFR/PDGFR inhibition potentiates antiangiogenic efficacy and reduces resistance to therapy, 79 and this approach is currently being evaluated in clinical trials.”
• Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex (2010, background): “In recent years, inhibiting PDGF-PDGFR signaling has become an attractive pursuit in anticancer therapy (4), and combined inhibition of PDGF and VEGF has emerged as a promising strategy for suppressing angiogenesis in tumor progression (12, 13).”
• PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. (2009, background): “Previous studies suggested that a combination of VEGF antagonists with PDGFR inhibitors, such as imatinib, might be a particularly effective anticancer strategy (Bergers et al., 2003; Erber et al., 2004; Jo et al., 2006).”
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. (2004, background): “VEGF/VEGFR inhibition can decrease the diameter, tortuosity, and permeability of tumor vessels(28) and even transform surviving tumor vessels into a more normal phenotype.(32,33) Considering the important role of VEGF and its receptors in regulating vascular function, we sought to characterize the c”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Pre-clinical studies have identified numerous candidates including angiopoietins [129], Bv8; Bombina variagata peptide 8 [134], EGF; epidermal growth factor [135], the DeltaNotch pathway [136], FGF1 and FGF2; fibroblast growth factors 1 and 2 [137, 138], HGF; hepatocyte growth factor [139], IL-8; in”